Patents Examined by William Lee
  • Patent number: 9895367
    Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: February 20, 2018
    Assignee: NATCO PHARMA LIMITED
    Inventors: Durga Maheswari Parvataneni, Siddhartha Yedluri, Venkata Satyanarayana Appadwedula, Kali Satya Bhujanga Rao, Venkaiah Chowdary Nannapaneni
  • Patent number: 9868697
    Abstract: A phytosphingosine derivative of chemical formula IA or IB, and a composition comprising the phytosphingosine derivative for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratotic diseases. The phytosphingosine derivatives of the present disclosure are involved with transcription factors related to inflammation, autoimmune diseases and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: January 16, 2018
    Assignee: The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventors: Byung-Hak Kim, Tae-Yoon Kim, Sanghee Kim
  • Patent number: 9856240
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: January 2, 2018
    Assignee: CALCIMEDICA, INC.
    Inventors: Jianguo Cao, Jeffrey P. Whitten, Zhijun Wang, Evan Rogers, Jonathan Grey
  • Patent number: 9855260
    Abstract: The present invention relates to compounds of the formula (I), salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds as activators of AMPK.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: January 2, 2018
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Alain Claude-Marie Daugan, Yann Lamotte, Olivier Mirguet
  • Patent number: 9828344
    Abstract: The invention relates to dihydropyridine compounds as inhibitors of the notch signalling pathway and/or inhibitors of secretion for the treatment of secretion-dependent disease, such as cancer or senescence-related ageing, in addition to pharmaceutical compositions thereof and methods of treatment.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: November 28, 2017
    Assignee: LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG FRITZ-LIPMANN-INSTITUT E.V. (FLI)
    Inventors: Christoph Kaether, Andreas Krämer
  • Patent number: 9808012
    Abstract: A biocidal composition comprising tributyl tetradecyl phosphonium chloride and tetrakis(hydroxymethyl)phosphonium sulfate at a weight ratio of 2:1 to 1:10, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: November 7, 2017
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Kathy Jing Ji, Zheng Q. Wen
  • Patent number: 9795559
    Abstract: The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: October 24, 2017
    Assignee: Recro Pharma, Inc.
    Inventors: Geraldine A. Henwood, Randall J. Mack, John Joseph Koleng, Jr., Christopher T. Sharr, Charles Alexander Freyer
  • Patent number: 9795568
    Abstract: The invention relates to a solid tablet that is directly-compressed of powder, comprising meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: October 24, 2017
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Martin A. Folger, Stefan Lehner, Horst Schmitt
  • Patent number: 9775903
    Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: October 3, 2017
    Assignees: JOHNS HOPKINS UNIVERSITY, OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
  • Patent number: 9770464
    Abstract: The present invention relates to methods for treating optic disorders or for reducing or alleviating the signs, symptoms, or pathological conditions related to such optic disorders. In particular, methods are provided for treating optic disorders, or reducing the symptoms thereof, the methods involving the administration of one or more downstream folate compounds and/or methyl-B12. In one particular embodiment, the method comprises administration of L-methylfolate. In other embodiments, the method involves administering both L-methylfolate and methyl-B12. In still further embodiments, the method further involves reducing dietary intake of folic acid. In certain embodiments, the method further involves identifying a subject organism with a malfunction in one or more of the folate or B4 cycles. In certain embodiments, such a malfunction is one or more of the C677T and A1298C mutations.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: September 26, 2017
    Inventor: Brian W Buell
  • Patent number: 9765029
    Abstract: The invention relates to substituted pyridine compounds of Formula I: (I) or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein A1, X, A2, R1a, R1b, R1c, G, and z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: September 19, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Don Kyle, Chiyou Ni, Minnie Park, Laykea Tafesse
  • Patent number: 9758465
    Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: September 12, 2017
    Assignee: United Therapeutics Corporation
    Inventor: Peter Laing
  • Patent number: 9750742
    Abstract: The invention includes compositions comprising a selective small-molecule inhibitor of RAD51 recombinase and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: September 5, 2017
    Assignee: Drexel University
    Inventors: Alexander V. Mazin, Fei Huang
  • Patent number: 9750691
    Abstract: A composition comprising an INTEROMONE® is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the INTEROMONE® is a naturally occurring pheromone.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: September 5, 2017
    Assignee: Sergeant's Pet Care Products, Inc.
    Inventors: John McGlone, Larry Nouvel
  • Patent number: 9744146
    Abstract: A method for alleviating at least one of the disturbance of bile acid metabolism, the disturbance of amino acid metabolism, and the disturbance of gut microbiota metabolism in a subject, comprising administering to the subject a composition or a health food comprising an active component selected from the group consisting of gallic acid, a pharmaceutically acceptable salt of gallic acid, a pharmaceutically acceptable ester of gallic acid, and combinations thereof.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: August 29, 2017
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Wen-Huang Peng, Li-Heng Pao, Jung Chao, Hao-Yuan Cheng, Meng-Shiou Lee
  • Patent number: 9726659
    Abstract: Provided are methods for identifying or monitoring a subject having, or at risk of developing, impaired glucose homeostasis. Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) is shown to be a biomarker for impaired glucose homeostasis and/or conditions characterized by ?-cell dysfunction. Comparing a test level of CMPF in a subject to a control level identifies subjects having, or at risk of developing, impaired glucose homeostasis. Also provided are methods of causing impaired glucose homeostasis or ?-cell dysfunction and methods of screening for compounds that affect the activity of ?-cells. Also provided are methods for the treatment of ?-cell dysfunction by reducing the physiological levels of CMPF in a subject as well as the use of a OAT modulator for the treatment of ?-cell dysfunction.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: August 8, 2017
    Assignee: The Governing Council of the University of Toronto
    Inventors: Michael Wheeler, Kacey Prentice, Feihan Dai, Ravi Retnakaran
  • Patent number: 9717726
    Abstract: A method of treating diarrhea in a patient includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 1, 2017
    Assignee: Maregade RX, LLC
    Inventor: Reed B Hogan, II
  • Patent number: 9700584
    Abstract: The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and the putties have excellent physical properties. The present disclosure relates to osteoinductive putties, carriers, compositions, implants, kits, methods of making and methods of using any of the foregoing.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: July 11, 2017
    Assignee: RTI Surgical, Inc.
    Inventor: Jordan Michael Katz
  • Patent number: 9693988
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following, application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 4, 2017
    Assignee: DOW PHARMACEUTICAL SCIENCES, INC.
    Inventors: Yunik Chang, Gordon J. Dow
  • Patent number: 9688620
    Abstract: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: June 27, 2017
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Sung James Lee, Susan Marie Melnick